Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison

BACKGROUND: Patients with multiple sclerosis (MS) experience relapses and sustained disability progression. Since 2004, the number of disease-modifying therapies (DMTs) for MS has grown substantially. As a result, patients, healthcare providers, and insurers are increasingly interested in comparativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohan, Stanley, Kumar, Jinender, Arndorfer, Stella, Zhu, Xuelian, Zivkovic, Marko, Tencer, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310468/
https://www.ncbi.nlm.nih.gov/pubmed/33847901
http://dx.doi.org/10.1007/s40263-021-00805-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310468/
https://www.ncbi.nlm.nih.gov/pubmed/33847901
http://dx.doi.org/10.1007/s40263-021-00805-0

Ejemplares similares